Therapeutic drug monitoring (TDM) doesn’t appear to improve clinical outcomes in patients with rheumatic diseases starting infliximab therapy. Presented at ACR Convergence 2020, the Norwegian Drug Monitoring Trial (NOR-DRUM) is believed to be the first RCT to compare TDM versus a standard approach to dosing in patients with any approved indication for infliximab. Part A ...
Patients on TNFi have no efficacy benefit from TDM
By Mardi Chapman
10 Nov 2020